1. Show article details.

    Cidara Therapeutics Named a San Diego Metro Area Top Workplace for the Fourth Consecutive Year

    GlobeNewswire – 8:00 AM ET 11/16/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the fourth consecutive year.

  2. Show article details.

    Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

    GlobeNewswire – 4:05 PM ET 11/11/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two upcoming conferences: the Stifel 2020 Virtual Healthcare Conference and 3rd Annual Evercore ISI HealthCON...

  3. Show article details.

    BRIEF-Cidara Provides Corporate Update And Reports Third Quarter 2020 Financial Results

    Reuters – 4:56 PM ET 11/05/2020

    Cidara Therapeutics Inc (CDTX): * CIDARA PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS. * NOW ANTICIPATE TOP-LINE DATA FROM RESTORE TRIAL BY END OF 2021. * CASH, CASH EQUIVALENTS AND RESTRICTED CASH TOTALED $53.7 MILLION AS OF SEPTEMBER 30, 2020. * QTRLY TOTAL REVENUES $2.4 MILLION VERSUS $19.1 MILLION.

  4. Show article details.

    Cidara Provides Corporate Update and Reports Third Quarter 2020 Financial Results

    GlobeNewswire – 4:24 PM ET 11/05/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended September 30, 2020, and provided an update on its corporate activities.

  5. Show article details.

    BRIEF-Cidara Therapeutics Announces New Clinical And Preclinical Data For Rezafungin And Influenza Avcs At Idweek 2020

    Reuters – 8:24 AM ET 10/21/2020

    Cidara Therapeutics Inc (CDTX): * CIDARA THERAPEUTICS ANNOUNCES NEW CLINICAL AND PRECLINICAL DATA FOR REZAFUNGIN AND INFLUENZA AVCS AT IDWEEK 2020 Source text for Eikon: Further company coverage:

  6. Show article details.

    Cidara Therapeutics Announces New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020

    GlobeNewswire – 8:00 AM ET 10/21/2020

    Presentations highlight clinical and preclinical progress of long-acting drug candidates for serious fungal and viral infections Posters presenting new analyses from completed Phase 2 STRIVE trial support the efficacy and pharmacokinetics of once-weekly rezafungin in the treatment of candidemia and invasive candidiasis Oral and poster presentations highlight potential of antiviral conjugates fo...

  7. Show article details.

    Cidara Therapeutics to Present at the 2020 American College of Clinical Pharmacy (ACCP) Annual Meeting

    GlobeNewswire – 8:00 AM ET 10/13/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two posters at the 2020 American College of Clinical Pharmacy Annual Meeting, which takes place virtually from October 19-30, 2020.

  8. Show article details.

    Cidara Therapeutics to Present New Clinical and Preclinical Data for Rezafungin and Influenza AVCs at IDWeek 2020

    GlobeNewswire – 8:00 AM ET 09/14/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two oral abstracts and seven posters at IDWeek 2020, the joint annual meeting of the Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, t...

  9. Show article details.

    Cidara Therapeutics to Participate in Upcoming Investor Conferences

    GlobeNewswire – 8:00 AM ET 09/02/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in four investor conferences in September: Citi’s 15th Annual BioPharma Conference, H.C. Wainwright 22nd Annual Global In...

  10. Show article details.

    Cidara Provides Corporate Update and Reports Second Quarter 2020 Financial Results

    GlobeNewswire – 4:48 PM ET 08/13/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended June 30, 2020, and provided an update on its corporate activities and product pipeline.

  11. Show article details.

    Cidara Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

    GlobeNewswire – 8:00 AM ET 08/04/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020.

  12. Show article details.

    Cidara Therapeutics Announces Formation of Scientific Advisory Board

    GlobeNewswire – 8:00 AM ET 07/27/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced the formation of a scientific advisory board and the appointment of four leading experts in viral and fungal infections and hematology.

  13. Show article details.

    Cidara Therapeutics to Participate in B. Riley Virtual Summer Series Panel on Antiviral Therapeutics

    GlobeNewswire – 8:00 AM ET 07/17/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the B. Riley FBR Virtual Summer Series panel on antiviral therapeutics on Tuesday, July 21, 2020.

  14. Show article details.

    Cidara Therapeutics Added to Russell 3000® Index

    GlobeNewswire – 8:00 AM ET 06/29/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that it has been added to the Russell 3000® Index at the conclusion of the Russell indexes annual reconstitution, effective upon the U.S. market open today, June 29, 2020.

  15. Show article details.

    Cidara Therapeutics to Participate in Cantor Fitzgerald Virtual Symposium: Winning Ways to Treat Infections and COVID-19

    GlobeNewswire – 8:00 AM ET 06/23/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Cantor Fitzgerald “Winning Ways to Treat Infections and COVID-19” Virtual Symposium on Tuesday, June 30, 2020.

  16. Show article details.

    Cidara Therapeutics to Present at the Raymond James Human Health Innovations Conference

    GlobeNewswire – 8:00 AM ET 06/11/2020

    Cidara Therapeutics, Inc. (CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present virtually at the Raymond James Human Health Innovations Conference on Thursday, June 18, 2020.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Nov
    05

    CDTX announced Q3 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.